

Bogdana Suchorska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2914055/publications.pdf>

Version: 2024-02-01

30
papers

1,869
citations

430874

18
h-index

501196

28
g-index

30
all docs

30
docs citations

30
times ranked

1982
citing authors

#	ARTICLE	IF	CITATIONS
1	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. <i>Neuro-Oncology</i> , 2016, 18, 1199-1208.	1.2	566
2	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial. <i>Neuro-Oncology</i> , 2016, 18, 549-556.	1.2	187
3	MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1021-1029.	6.4	160
4	Biological tumor volume in ¹⁸ F-FET-PET before radiochemotherapy correlates with survival in GBM. <i>Neurology</i> , 2015, 84, 710-719.	1.1	144
5	Prognostic Significance of Dynamic ¹⁸ F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 9-15.	5.0	144
6	Dynamic ¹⁸ F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 198-203.	5.0	123
7	Identification of time-to-peak on dynamic ¹⁸ F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. <i>Neuro-Oncology</i> , 2018, 20, 279-288.	1.2	71
8	Serial ¹⁸ F-FET PET Imaging of Primarily ¹⁸ F-FET–Negative Glioma: Does It Make Sense?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1177-1182.	5.0	56
9	[¹⁸ F]Fluoroethyltyrosine—Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma. <i>Molecular Imaging</i> , 2013, 12, 7290.2012.00027.	1.4	36
10	PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging. <i>Frontiers in Oncology</i> , 2021, 11, 646387.	2.8	35
11	Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic ¹⁸ F-FET PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2581-2589.	6.4	34
12	Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection. <i>Neuro-Oncology</i> , 2011, 13, 1133-1142.	1.2	33
13	PET imaging for brain tumor diagnostics. <i>Current Opinion in Neurology</i> , 2014, 27, 683-688.	3.6	32
14	Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning. <i>European Journal of Cancer</i> , 2019, 107, 15-27.	2.8	30
15	Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [¹⁸ F]FET PET radiomics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4415-4425.	6.4	29
16	¹⁸ F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy. <i>Journal of Neuro-Oncology</i> , 2018, 139, 721-730.	2.9	28
17	[¹⁸ F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. <i>Molecular Imaging</i> , 2013, 12, 137-47.	1.4	24
18	Use of PET Imaging in Neuro-Oncological Surgery. <i>Cancers</i> , 2021, 13, 2093.	3.7	23

#	ARTICLE	IF	CITATIONS
19	Voxel-wise analysis of dynamic 18F-FET PET: a novel approach for non-invasive glioma characterisation. EJNMMI Research, 2018, 8, 91.	2.5	20
20	Usefulness of PET Imaging to Guide Treatment Options in Gliomas. Current Treatment Options in Neurology, 2016, 18, 4.	1.8	16
21	O-(2-[18F]fluoroethyl)-l-tyrosine PET in gliomas: influence of data processing in different centres. EJNMMI Research, 2017, 7, 64.	2.5	14
22	PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. Journal of Neuro-Oncology, 2021, 153, 283-291.	2.9	13
23	L-type amino acid transporter (LAT) 1 expression in 18F-FET-negative gliomas. EJNMMI Research, 2021, 11, 124.	2.5	13
24	The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 267-271.	0.7	12
25	Comment on "Hypometabolic gliomas on FET-PET" is there an inverted U-curve for survival? Neuro-Oncology, 2019, 21, 1612-1613.	1.2	9
26	Role of amino-tracer PET for decision-making in neuro-oncology. Current Opinion in Neurology, 2018, 31, 720-726.	3.6	8
27	18F-FET PET Uptake Characteristics of Long-Term IDH-Wildtype Diffuse Glioma Survivors. Cancers, 2021, 13, 3163.	3.7	5
28	TERT-Promoter Mutational Status in Glioblastoma " Is There an Association With Amino Acid Uptake on Dynamic 18F-FET PET?. Frontiers in Oncology, 2021, 11, 645316.	2.8	4
29	PATH-04. INFLUENCE OF INDIVIDUAL CpG METHYLATION STATUS OF THE MGMT PROMOTOR ON OUTCOME IN ADULT PATIENTS WITH GLIOBLASTOMA MULTIFORME RECEIVING ALKYLATING AGENT TREATMENT. Neuro-Oncology, 2019, 21, vi143-vi143.	1.2	0
30	Case 25: Primary Diagnosis of an Isocitrate Dehydrogenase (IDH) Wild-Type Glioma. , 2022, , 125-128.		0